Greener route to tirzepatide synthesis

A study published in the Journal of the American Chemical Society on 11 June 2026 describes a combined approach to peptide manufacturing that pairs tag-assisted peptide synthesis (TAPS) with aryl selenoester aminolysis ligation (ASAL) to assemble therapeutic peptides up to 39 amino acids long, with minimal epimerization and sharply reduced solvent and reagent consumption^[1]. The method was demonstrated on three marketed peptide drugs, including tirzepatide, and could reshape how the pharmaceutical industry manufactures the growing class of peptide-based medicines.

The manufacturing problem

Most peptide drugs today are built using solid-phase peptide synthesis (SPPS), a method developed in the 1960s. SPPS anchors a growing peptide chain to a resin bead and adds one amino acid at a time. It works well for short sequences, but as peptides get longer, yields drop, purification becomes harder, and the process generates large volumes of organic solvent waste. For a 39-residue peptide like tirzepatide, the solvent and reagent burden is substantial^[2].

This matters because demand for peptide therapeutics is surging. GLP-1 receptor agonists alone represent a market measured in tens of billions of dollars annually, and newer dual- and triple-agonist peptides are longer and more structurally complex than earlier generations. Manufacturing capacity and environmental impact are real constraints on how quickly these drugs can reach patients.

How TAPS and ASAL work together

TAPS replaces the solid resin with a soluble chemical tag that keeps the growing peptide dissolved in the reaction mixture. Because the chemistry happens in solution rather than on a bead surface, reaction kinetics are faster, aggregation is less of a problem, and the process can be monitored in real time. After each coupling step, the tagged peptide is separated from reagents by a simple precipitation or filtration, avoiding the large solvent washes that SPPS demands. Industry data from contract manufacturers using TAPS report greater than 90 percent reduction in organic solvent waste and roughly 50 percent less amino acid and coupling reagent consumption compared with conventional routes^[3].

The limitation of TAPS, until now, has been peptide length. Building chains longer than about 20 residues in a single run becomes unreliable. The new study overcomes this by splitting the target peptide into two or three fragments, each synthesized separately by TAPS, and then joining them using ASAL. In this ligation step, one fragment carries an aryl selenoester at its C-terminus and the other has a free N-terminal amine. The selenoester reacts rapidly with the amine to form a native peptide bond. The authors report that this ligation proceeds with minimal epimerization, meaning the stereochemistry of the amino acids is preserved^[1].

What the researchers demonstrated

The team applied their TAPS-plus-ASAL strategy to three therapeutic peptides: teriparatide (34 residues, used to treat osteoporosis), taspoglutide-related intermediates (32 residues), and tirzepatide (39 residues, an FDA-approved GLP-1/GIP dual agonist for type 2 diabetes and obesity). All three were assembled from TAPS-synthesized fragments joined by ASAL^[1].

Tirzepatide is a useful test case because it is among the longest and most complex synthetic peptides in current clinical use. Its 39-residue sequence includes a fatty-acid modification that adds further synthetic difficulty. If TAPS-ASAL can handle tirzepatide, the approach is likely applicable to most peptide therapeutics on the market or in development.

Why sustainability matters for peptide drugs

Peptide manufacturing has a waste problem. Existing hybrid SPPS/LPPS routes for tirzepatide involve high process mass intensity, and multiple research groups have recently published alternative synthesis strategies in an effort to cut costs and environmental burden^[2]. As production volumes rise to meet global demand for GLP-1-class drugs, the environmental footprint of peptide synthesis becomes a significant concern for manufacturers and regulators alike.

TAPS-ASAL addresses this at the chemistry level: fewer solvents, less reagent excess, and a convergent fragment strategy that avoids building the entire chain in one long, inefficient run. The approach also uses existing reactor and filtration equipment, which lowers the capital barrier for manufacturers considering a switch from pure SPPS.

What this does not tell us

The JACS paper is a proof-of-concept demonstration, not a commercial manufacturing study. The authors showed that the chemistry works at laboratory scale, but translating any synthesis method from bench to multi-kilogram GMP production involves additional challenges: process validation, impurity profiling at scale, regulatory filing, and cost comparison with established routes^[1].

The study does not report overall isolated yields for the final therapeutic peptides, which would be needed to assess commercial viability. It also does not compare head-to-head with the hybrid SPPS/LPPS methods that some manufacturers already use for tirzepatide. And while the epimerization data are promising, long-term stability and purity under scaled conditions remain open questions.

For patients, the practical impact of this research is indirect. Advances in peptide manufacturing may eventually translate into lower costs and wider availability of drugs like tirzepatide, but that outcome depends on adoption by pharmaceutical companies, regulatory approval of new manufacturing processes, and pricing decisions that are outside the scope of bench chemistry. If you are taking or considering a peptide-based medication, consult your healthcare provider about options available today.